Emergent BioSolutions Inc. (0IGA.L)
0IGA.L Stock Price Chart
Explore Emergent BioSolutions Inc. interactive price chart. Choose custom timeframes to analyze 0IGA.L price movements and trends.
0IGA.L Company Profile
Discover essential business fundamentals and corporate details for Emergent BioSolutions Inc. (0IGA.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
900.00
CEO
Joseph C. Papa Jr.,
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
0IGA.L Financial Timeline
Browse a chronological timeline of Emergent BioSolutions Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 4 Nov 2025
Upcoming earnings on 4 Aug 2025
Revenue estimate is $148.55M.
Earnings released on 7 May 2025
EPS came in at $0.71 surpassing the estimated $0.44 by +61.36%, while revenue for the quarter reached $222.20M, beating expectations by +1.46%.
Earnings released on 3 Mar 2025
EPS came in at -$0.58 falling short of the estimated -$0.50 by -14.73%, while revenue for the quarter reached $194.70M, missing expectations by -23.55%.
Earnings released on 7 Nov 2024
EPS came in at $1.37 surpassing the estimated $0.10 by +1.23K%, while revenue for the quarter reached $293.80M, beating expectations by +13.44%.
Earnings released on 7 Aug 2024
EPS came in at -$5.38 falling short of the estimated -$1.14 by -374.20%, while revenue for the quarter reached $254.70M, beating expectations by +34.05%.
Earnings released on 2 May 2024
EPS came in at $0.17 surpassing the estimated -$0.98 by +117.59%, while revenue for the quarter reached $300.40M, beating expectations by +36.39%.
Earnings released on 7 Mar 2024
EPS came in at -$0.95 falling short of the estimated -$0.19 by -402.32%, while revenue for the quarter reached $276.60M, missing expectations by -5.73%.
Earnings released on 9 Nov 2023
EPS came in at -$5.08 falling short of the estimated -$0.22 by -2.18K%, while revenue for the quarter reached $270.50M, beating expectations by +13.93%.
Earnings released on 9 Aug 2023
EPS came in at -$5.15 falling short of the estimated -$0.65 by -696.98%, while revenue for the quarter reached $337.90M, beating expectations by +56.31%.
Earnings released on 10 May 2023
EPS came in at -$3.65 falling short of the estimated -$1.29 by -181.72%, while revenue for the quarter reached $165.10M, beating expectations by +3.36%.
Earnings released on 28 Feb 2023
EPS came in at -$1.76 falling short of the estimated $0.04 by -4.11K%, while revenue for the quarter reached $330.70M, beating expectations by +11.28%.
Earnings released on 30 Sept 2022
EPS came in at -$1.52 falling short of the estimated -$0.06 by -2.36K%, while revenue for the quarter reached $240.00M, missing expectations by -10.55%.
Earnings released on 30 Jun 2022
EPS came in at -$1.13 falling short of the estimated $0.38 by -396.84%, while revenue for the quarter reached $242.70M, missing expectations by -10.42%.
Earnings released on 31 Mar 2022
EPS came in at -$0.07 falling short of the estimated $0.13 by -158.38%, while revenue for the quarter reached $307.50M, beating expectations by +8.44%.
Earnings released on 9 Jan 2022
EPS came in at $3.50 falling short of the estimated $4.23 by -17.26%, while revenue for the quarter reached $723.20M, beating expectations by +8.09%.
Earnings released on 4 Nov 2021
EPS came in at $0.09, while revenue for the quarter reached $397.50M.
Earnings released on 30 Sept 2021
EPS came in at -$0.61, while revenue for the quarter reached $329.00M.
Earnings released on 31 Mar 2021
EPS came in at $1.28, while revenue for the quarter reached $343.00M.
Earnings released on 31 Dec 2020
EPS came in at $3.42, while revenue for the quarter reached $583.00M.
Earnings released on 30 Sept 2020
EPS came in at $0.73, while revenue for the quarter reached $385.20M.
0IGA.L Stock Performance
Access detailed 0IGA.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.